Loading clinical trials...
Loading clinical trials...
A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous CCI-779 Given Once Daily for 5 Days Every 2 Weeks to Patients With Advanced Solid Tumors
Conditions
Interventions
temsirolimus
Locations
2
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
San Antonio Cancer Institute
San Antonio, Texas, United States
Start Date
January 1, 2001
Primary Completion Date
June 1, 2002
Completion Date
June 1, 2002
Last Updated
August 9, 2012
NCT04657068
NCT07197671
NCT04585750
NCT05831579
NCT04900818
NCT07269080
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions